

2016

Senate Bill 486 Evaluation Team  
CONSUMER REPORT CARD



**SUMMARY:**

The legislatively mandated deadline for report submission was July 1, 2016. There were 25 plans submitted to the State of California which posted them on their website for public consumption. These plans were read and graded by an evaluation team, scoring each plan based on published consumer criteria. There were:

- Four "A" grade plans;
- One “B” grade plan;
- Two "C" grade plans;
- Nineteen "F" grade plans.
- In addition, Sixteen “F/Incomplete” grade plans were given for those manufacturers who did not submit plans by the legislatively mandated deadline of July 1 or did not submit plans whatsoever.

All but five manufacturers resubmitted or retyped their 2011, 2012, 2013, 2014 or 2015 plans verbatim or almost verbatim and those are indicated with an asterisk (\*). Plans that were submitted **after** the legislatively mandated July 1 deadline are marked with a (∞).

<u>Manufacturer</u>	<u>Score</u>	<u>Grade</u>
Alexion*	10	F
Amgen	90	A
AstraZeneca*	14	F
Bayer	21	F
Biogen	20	F
Bristol Meyers Squibb		
Orencia	80	B
Other drugs	0 -43	F
CSL Behring*	2	F
Dr. Reddy’s Lab	9	F
Eli Lilly & Co.*	13	F
EMD Serono*∞	93	A
Genentech/Roche*	46	F
GlaxoSmithKline*	42	C
Grifols, Inc.*	15	F
Janssen Biotech, Inc.* ∞	94	A
Kaleo*	10	F
Merck *	32	F
Novartis*		
Signifor	75	C
Cosentyx	90	A
Perrigo*∞	5	F
Pfizer*	25	F
Sandoz*	3	F
Sanofi-Aventis*	47	F
Shire*	3	F
Teva*	20	F
UCB, Inc.* ∞	17	F

**THE FOLLOWING DRUG  
MANUFACTURERS ARE IN  
VIOLATION OF STATE LAW DUE TO  
THE FACT THAT THEY DID NOT  
SUBMIT ANY PLANS TO THE STATE IN  
2014 YET MAKE HOME INJECTABLE  
MEDICATION SUBJECT TO SB 486:**

<b><u>Manufacturer</u></b>	<b><u>Grade</u></b>
Biovitrium (no plan on file since law went into effect in 2010)	F
Baxter (last plan on file: 2012, authored in 2010)	F
Dey Pharmaceuticals (last plan on file: 2011)	F
Eisai (last plan on file: 2014)	F
Ferring Pharmaceuticals (last submitted in 2011)	F
Hospira (last plan on file: 2011- claim they are not subject to SB 486)	F
InterMune (last plan on file: 2011)	F
Ipsen (last plan on file: 2011)	F
JHP (last plan on file: 2015)	F
Kadmon (last plan on file: 2013)	F
NPS (last plan on file: 2013)	F
Novo Nordisk (last plan on file: 2011)	F
Mallinckrodt (Questcor) Pharmaceuticals (no plan on file since law went into effect in 2010)	F
Salix (last plan on file: 2012)	F
Viro (last plan on file: 2013)	F
Zoegenix (no plan on file since law went into effect in 2010; manufacturer claims they have a proprietary “needle-free” subcutaneous injection delivery system and aren’t subject to SB 486)	F